Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Jefferies Reiterates Buy on Bristol-Myers Squibb (BMY) Following a 2017 Outlook
January 5, 2017 8:38 AM ESTJefferies reiterated a Buy rating and $69.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following a 2017 outlook.
Analyst Jeffrey Holford commented, "We expect 2017 to be a year of strong recovery for BMY as the CM-568 and CM-227 studies deliver data that... More
